Welcome to our dedicated page for AgomAb Therapeutics NV SEC filings (Ticker: AGMB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agomab Therapeutics NV filings document the company's foreign private issuer reports, ADS public offering disclosures, governance materials, and clinical-stage biopharmaceutical updates. Form 6-K reports have included the closing of the company's initial public offering of American Depositary Shares, amended and restated articles of association, press releases, annual meeting materials, proxy forms, and voting documentation.
AGMB's regulatory record also discloses capital-structure matters tied to ADSs and common shares, incorporation of materials into a Form S-8 registration statement, financial results, business updates, shareholder voting matters, and clinical or regulatory disclosures related to its fibro-inflammatory disease programs.
AgomAb Therapeutics NV received a Schedule 13D filing from investment entities LSP 7 Cooperatieve U.A. and LSP 7 Management B.V., which together report beneficial ownership of 5,141,992 common shares, representing about 10.6% of AgomAb’s 48,736,779 common shares outstanding as of February 9, 2026.
LSP 7 accumulated its position through pre-IPO preferred stock purchases of approximately €40 million that converted into 4,016,992 common shares at the IPO, plus a purchase of 1,125,000 American Depositary Shares at $16.00 per share on the IPO closing date. The investors are party to an amended and restated shareholders’ agreement providing registration rights for resale of certain shares and have agreed to a 180‑day lock-up restricting sales after the IPO closing.
The filing states that the investors may, from time to time, buy more shares, hold, or sell, and may discuss strategic alternatives with AgomAb’s management, board, other shareholders, and third parties, potentially including mergers, asset transactions, capital structure changes, or board composition changes. One of their designees, Felice Verduyn‑van Weegen, serves on AgomAb’s board of directors.
Agomab Therapeutics NV has completed its initial public offering of 12,500,000 American Depositary Shares (“ADSs”) on the Nasdaq Global Select Market under the ticker “AGMB”. The ADSs were priced at $16.00 per ADS, generating aggregate gross proceeds of approximately $200.0 million before expenses.
The company also implemented amended and restated articles of association effective with the IPO and furnished related press releases covering the launch, pricing and closing of the offering.
AgomAb Therapeutics is conducting an initial public offering of $200,000,000 by offering 12,500,000 ADSs at $16.00 per ADS, with an underwriter option for up to 1,875,000 ADSs; ADSs will trade on Nasdaq under the symbol AGMB.
The prospectus states estimated net proceeds of approximately $181 million to advance clinical development of ontunisertib and AGMB-447, fund preclinical programs, a milestone payment related to the Origo acquisition, and general corporate purposes. The company is an emerging growth company and a foreign private issuer, reports under IFRS, and expects delivery of ADSs on February 9, 2026.